A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma (Q33332855)

25 July 2017

A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma (English)

1 reference

25 July 2017

1 reference

Small EJ

1

1 reference

25 July 2017

Figlin R

2

1 reference

25 July 2017

Petrylak D

3

1 reference

25 July 2017

Vaughn DJ

4

1 reference

25 July 2017

Sartor O

5

1 reference

25 July 2017

Horak I

6

1 reference

25 July 2017

Pincus R

7

1 reference

25 July 2017

Kremer A

8

1 reference

25 July 2017

Bowden C

9

1 reference

25 July 2017

1 May 2000

1 reference

Investigational New Drugs

25 July 2017

1 reference

25 July 2017

18

1 reference

25 July 2017

193-197

1 reference

25 July 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1006386115312

25 July 2017

0 references

cites work

Cancer statistics, 1998.

1 reference

12 December 2020

Phase I study of adozelesin administered by 24-hour continuous intravenous infusion

1 reference

12 December 2020

Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors

1 reference

12 December 2020

CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents

1 reference

12 December 2020

Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.

1 reference

12 December 2020

Anticellular and antitumor activity of duocarmycins, novel antitumor antibiotics

1 reference

12 December 2020

A novel antitumor antibiotic, KW-2189 is activated by carboxyl esterase and induces DNA strand breaks in human small cell lung cancer cells

1 reference

12 December 2020

1 reference

12 December 2020

Differential effect of duocarmycin A and its novel derivative DU-86 on DNA strand breaks in HeLa S3 cells.

1 reference

12 December 2020

Analysis of DNA fragmentation in human uterine cervix carcinoma HeLa S3 cells treated with duocarmycins or other antitumor agents by pulse field gel electrophoresis.

1 reference

12 December 2020

Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.

1 reference

12 December 2020

Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

1 reference

12 December 2020

Standard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma.

1 reference

12 December 2020

The reversible DNA-alkylating activity of duocarmycin and its analogues

1 reference

12 December 2020

The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon

1 reference

12 December 2020

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

12 December 2020

Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administrat

1 reference

12 December 2020

Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma: a phase II study

1 reference

12 December 2020

Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11.

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.

1 reference

12 December 2020

Structures of duocarmycins, novel antitumor antibiotics produced by Streptomyces sp.

1 reference

12 December 2020

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1006386115312

1 reference

Dimensions Publication ID

25 July 2017

0 references

1 reference